CVS Health Corporation $CVS Position Lifted by Payden & Rygel

Payden & Rygel grew its position in CVS Health Corporation (NYSE:CVS) by 19.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 260,340 shares of the pharmacy operator’s stock after acquiring an additional 41,640 shares during the quarter. CVS Health comprises about 1.7% of Payden & Rygel’s portfolio, making the stock its 15th largest position. Payden & Rygel’s holdings in CVS Health were worth $22,309,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CVS. CHICAGO TRUST Co NA increased its stake in CVS Health by 59.3% in the third quarter. CHICAGO TRUST Co NA now owns 10,829 shares of the pharmacy operator’s stock worth $928,000 after purchasing an additional 4,029 shares during the period. Parcion Private Wealth LLC lifted its position in shares of CVS Health by 10.3% during the third quarter. Parcion Private Wealth LLC now owns 4,826 shares of the pharmacy operator’s stock worth $414,000 after purchasing an additional 449 shares during the last quarter. Soltis Investment Advisors LLC boosted its stake in shares of CVS Health by 71.6% during the third quarter. Soltis Investment Advisors LLC now owns 11,358 shares of the pharmacy operator’s stock valued at $973,000 after purchasing an additional 4,739 shares during the period. United Asset Strategies Inc. increased its stake in CVS Health by 4.1% in the 3rd quarter. United Asset Strategies Inc. now owns 9,425 shares of the pharmacy operator’s stock worth $808,000 after buying an additional 368 shares during the period. Finally, Choreo LLC increased its stake in CVS Health by 3.8% in the 3rd quarter. Choreo LLC now owns 83,211 shares of the pharmacy operator’s stock worth $7,130,000 after buying an additional 3,049 shares during the period. Institutional investors own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Royal Bank Of Canada lifted their price target on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a research note on Thursday, July 9th. Wells Fargo & Company boosted their price target on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Argus boosted their price target on CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Finally, JPMorgan Chase & Co. increased their price objective on CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Nineteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $109.64.

CVS Health Trading Down 0.1%

NYSE CVS opened at $90.20 on Friday. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market capitalization of $115.36 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. The company’s 50-day simple moving average is $91.22 and its two-hundred day simple moving average is $88.76.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The company’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts forecast that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be issued a dividend of $0.6650 per share. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s dividend payout ratio is currently 70.37%.

CVS Health Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.